Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Milestone Pharmaceuticals Inc(MIST)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for MIST
11/13/2026: MIST (1-star) is currently NOT-A-BUY. Pass it for now.
Milestone Pharmaceuticals is a biotechnology company focused on delivering novel cardiovascular treatments, most notably through its recently approved nasal spray, Cardaizera. The firm's core strength lies in its innovative drug-delivery technology, which provides a non-invasive, patient-controlled alternative for treating episodic heart rhythm disorders. The primary investment story centers on the successful commercial adoption of Cardaizera and the potential for label expansion into other heart conditions. However, the company faces significant risks, including intense competition from large pharmaceutical incumbents, the need to secure favorable insurance coverage, and the execution challenges inherent in an early-stage launch. Milestone is best suited for growth-oriented investors who can tolerate the high volatility typical of commercial-stage biotechs.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers growth potential through product commercialization but carries the significant risks associated with an early-stage drug launch. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities if the uptake of Cardaizera accelerates and drives a positive trend in the stock price. |
| Value investor | Weak fit | The company is not currently profitable and does not have the stable earnings profile typical of a value investment. |
| Dividend investor | Weak fit | Milestone is a growth-oriented biotechnology company that does not pay dividends. |
| Low-risk investor | Weak fit | The high volatility and clinical/commercial risks inherent in small-cap biotechs are unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Small-cap biotech stocks frequently experience significant price swings based on news flow and commercial updates. |
| Valuation risk | Medium / high | Valuation is sensitive to long-term commercial success projections for a single main product. |
| Competition risk (Established Pharma) | High | Established players can leverage existing relationships to defend market share against new entrants. |
| Business quality | Medium | The company has a validated product but is in the difficult early stages of proving commercial viability. |
| Dividend income | Low / none | No dividend is paid, making the stock unsuitable for income-focused investors. |
| Execution risk | High | Successfully transitioning from clinical approval to widespread clinical adoption is a major hurdle for any new therapy. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 64.74M USD | Price to earnings Ratio - | 1Y Target Price 5.57 |
Price to earnings Ratio - | 1Y Target Price 5.57 | ||
Volume (30-day avg) 1.3M shares | Beta 1.06 | 52 Weeks Range 0.50 - 3.06 | Updated Date 11/14/2026 |
52 Weeks Range 0.50 - 3.06 | Updated Date 11/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.68 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -60.96% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cardiovascular Therapeutics | Revenue generated from the sale of Cardaizera (etripamil). | The company makes money primarily by selling its flagship cardiovascular nasal spray to patients and healthcare providers. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -29.31M | Price to Sales(TTM) 27.63 |
Enterprise Value -29.31M | Price to Sales(TTM) 27.63 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA -1.43 | Shares Outstanding 124.50M | Shares Floating 106.20M |
Shares Outstanding 124.50M | Shares Floating 106.20M | ||
Percent Insiders 0.7 | Percent Institutions 51.46 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.